Personalized biologic selection for adults with psoriasis and psoriatic arthritis with cardiovascular biomarker testing
Official title: A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
Run by Taichung Veterans General Hospital · NCT07149792 · Data updated 2026-11-12
This project will test whether a prescreen strategy can help doctors pick the most effective biologic medicine for adults (18–75) with psoriasis or psoriatic arthritis.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Taichung Veterans General Hospital Academic / other |
| Drugs / interventions | adalimumab, golimumab, certolizumab, ustekinumab, ixekizumab, secukinumab, guselkumab, risankizumab |
| Locations | 2 sites (Taichung, Taiwan and 1 other locations) |
| Status | Recruiting |
| Started | July 29, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | June 1, 2028 |
| Registry record updated | September 2, 2025 |
| Trial ID | NCT07149792 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with dermatologist-confirmed psoriasis or rheumatologist-confirmed psoriatic arthritis who can provide blood samples and do not have active infection, recent serious infection hospitalization, current cancer, or HIV are ideal candidates.
✕Probably not a fit
Patients with active infections, suspected or current malignancy, HIV infection, recent hospitalization for infection, or those unwilling/unable to provide blood samples are unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Forty adult patients with psoriasis, with or without psoriatic arthritis, were enrolled at multiple tertiary hospitals in Taiwan and randomized to either a prescreen strategy–based biologic selection group or a standard-based biologic selection group. Patients are followed through scheduled visits up to week 72, with possible extension to three years, and clinical endpoints include PASI as well as painful and swollen joint counts. The protocol also collects blood to isolate PBMCs, exposes them to Streptococcus pyogenes with and without a panel of biologics at trough-equivalent concentrations, and measures cytokine responses alongside cardiovascular biomarkers. The combined clinical and laboratory approach aims to link prescreen biomarker signals to real-world treatment responses.
Why it matters
Potential benefit: If successful, this approach could help match patients to biologics that control skin and joint symptoms more effectively and may identify signals related to cardiovascular risk.
How similar studies have gone: Precision prescreening to guide biologic choice has shown some promising pilot data but remains relatively novel and not yet widely validated for psoriasis and psoriatic arthritis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy subjects * Psoriasis patients * Psoriatic arthritis patients * Agree to provide a blood sample Exclusion Criteria: * A current history of cancer, * Recent hospitalization for infection or current antibiotic treatment * HIV infection.
Where it's running
-
Taichung Vertenans General Hospital
Taichung, Taiwan, Taiwan Recruiting -
Taichung Veterans Hospital
Taichung, Taiwan, Taiwan Not yet recruiting
Study contacts
- Study coordinator: James Yen, MD PhD
- Email: vernayen@yahoo.com.tw
- Phone: 886-4-23592525
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HB0017 Injection safety and PK in low-weight adults at different injection sites
This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.
-
MK-8644: first-in-human test in healthy people and people with psoriasis
This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care
This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.
-
TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis
This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.
-
SHR-1139 injectable treatment for adults with plaque psoriasis
This study tests whether an SHR-1139 injection works and is safe for adults with plaque psoriasis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.